VYNE Therapeutics Inc. (VYNE) News
Filter VYNE News Items
VYNE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VYNE News Highlights
- For VYNE, its 30 day story count is now at 4.
- Over the past 28 days, the trend for VYNE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest VYNE News From Around the Web
Below are the latest news stories about VYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate VYNE as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning! |
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual ConferenceBRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammation D |
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business UpdateFirst vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate topline Phase 1b data in mid-2023 BRIDGEWATER, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the four |
VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RuleBRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it received a notification letter (the "Notification Letter on Compliance") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on February 28, 2023, indicating |
VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care ConferenceBRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts |
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events from all dose cohorts, meeting the primary objective of the study Topline Phase 1b results in vitiligo patients expected in mid-2023 BRIDGEWATER, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today |
VYNE Therapeutics Announces Reverse Stock SplitCommon stock expected to begin trading on split-adjusted basis on February 13, 2023BRIDGEWATER, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that its Board of Directors has approved a reverse stock split of the Company’s common stock at a ratio of 1-for-18. The reverse stock sp |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! |
VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201First patient dosed follows swiftly from IND clearance and enrollment of first healthy volunteers in Phase 1a portion of study in November Topline data expected in 1H 2023 BRIDGEWATER, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the first vitiligo patient has been dosed i |